Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDA receptor

Alessandra Grossert, Narges Zare Mehrjardi, Sarah Bailey, Mark Lindsay, Jurgen Hescheler, Tomo Saric, Nicole Teusch

Research output: Contribution to journalArticle

Abstract

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine offers promising perspectives for the treatment of major depressive disorder. Although ketamine demonstrates rapid and long-lasting effects, even in treatment-resistant patients, to date, the underlying mode of action remains elusive. Thus, the aim of our study was to investigate the molecular mechanism of ketamine at clinically relevant concentrations by establishing an in vitro model based on human induced pluripotent stem cells (iPSCs)-derived neural progenitor cells (NPCs). Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment. Ketamine (1 µM) was able to increase cyclic adenosine monophosphate (cAMP) signaling in NPCs within 15 min and cell proliferation, while ketamine-induced IGF2 expression was reduced after PKA inhibition with cAMPS-Rp. Furthermore, 24 h post-administration of ketamine (15 mg/kg) in vivo confirmed phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in the subgranular zone (SGZ) of the hippocampus in C57BL/6 mice. In conclusion, ketamine promotes the proliferation of NPCs presumably by involving cAMP-IGF2 signaling.
Original languageEnglish
Article number1139
JournalCells
Volume8
Issue number10
DOIs
Publication statusPublished - 24 Sep 2019

Cite this

Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDA receptor. / Grossert, Alessandra; Mehrjardi, Narges Zare; Bailey, Sarah; Lindsay, Mark; Hescheler, Jurgen; Saric, Tomo; Teusch, Nicole.

In: Cells, Vol. 8, No. 10, 1139, 24.09.2019.

Research output: Contribution to journalArticle

Grossert, Alessandra ; Mehrjardi, Narges Zare ; Bailey, Sarah ; Lindsay, Mark ; Hescheler, Jurgen ; Saric, Tomo ; Teusch, Nicole. / Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDA receptor. In: Cells. 2019 ; Vol. 8, No. 10.
@article{358e02fc098f4999bae25f2bd38e7e9e,
title = "Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDA receptor",
abstract = "The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine offers promising perspectives for the treatment of major depressive disorder. Although ketamine demonstrates rapid and long-lasting effects, even in treatment-resistant patients, to date, the underlying mode of action remains elusive. Thus, the aim of our study was to investigate the molecular mechanism of ketamine at clinically relevant concentrations by establishing an in vitro model based on human induced pluripotent stem cells (iPSCs)-derived neural progenitor cells (NPCs). Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment. Ketamine (1 µM) was able to increase cyclic adenosine monophosphate (cAMP) signaling in NPCs within 15 min and cell proliferation, while ketamine-induced IGF2 expression was reduced after PKA inhibition with cAMPS-Rp. Furthermore, 24 h post-administration of ketamine (15 mg/kg) in vivo confirmed phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in the subgranular zone (SGZ) of the hippocampus in C57BL/6 mice. In conclusion, ketamine promotes the proliferation of NPCs presumably by involving cAMP-IGF2 signaling.",
author = "Alessandra Grossert and Mehrjardi, {Narges Zare} and Sarah Bailey and Mark Lindsay and Jurgen Hescheler and Tomo Saric and Nicole Teusch",
year = "2019",
month = "9",
day = "24",
doi = "10.3390/cells8101139",
language = "English",
volume = "8",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI",
number = "10",

}

TY - JOUR

T1 - Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDA receptor

AU - Grossert, Alessandra

AU - Mehrjardi, Narges Zare

AU - Bailey, Sarah

AU - Lindsay, Mark

AU - Hescheler, Jurgen

AU - Saric, Tomo

AU - Teusch, Nicole

PY - 2019/9/24

Y1 - 2019/9/24

N2 - The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine offers promising perspectives for the treatment of major depressive disorder. Although ketamine demonstrates rapid and long-lasting effects, even in treatment-resistant patients, to date, the underlying mode of action remains elusive. Thus, the aim of our study was to investigate the molecular mechanism of ketamine at clinically relevant concentrations by establishing an in vitro model based on human induced pluripotent stem cells (iPSCs)-derived neural progenitor cells (NPCs). Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment. Ketamine (1 µM) was able to increase cyclic adenosine monophosphate (cAMP) signaling in NPCs within 15 min and cell proliferation, while ketamine-induced IGF2 expression was reduced after PKA inhibition with cAMPS-Rp. Furthermore, 24 h post-administration of ketamine (15 mg/kg) in vivo confirmed phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in the subgranular zone (SGZ) of the hippocampus in C57BL/6 mice. In conclusion, ketamine promotes the proliferation of NPCs presumably by involving cAMP-IGF2 signaling.

AB - The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine offers promising perspectives for the treatment of major depressive disorder. Although ketamine demonstrates rapid and long-lasting effects, even in treatment-resistant patients, to date, the underlying mode of action remains elusive. Thus, the aim of our study was to investigate the molecular mechanism of ketamine at clinically relevant concentrations by establishing an in vitro model based on human induced pluripotent stem cells (iPSCs)-derived neural progenitor cells (NPCs). Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment. Ketamine (1 µM) was able to increase cyclic adenosine monophosphate (cAMP) signaling in NPCs within 15 min and cell proliferation, while ketamine-induced IGF2 expression was reduced after PKA inhibition with cAMPS-Rp. Furthermore, 24 h post-administration of ketamine (15 mg/kg) in vivo confirmed phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in the subgranular zone (SGZ) of the hippocampus in C57BL/6 mice. In conclusion, ketamine promotes the proliferation of NPCs presumably by involving cAMP-IGF2 signaling.

U2 - 10.3390/cells8101139

DO - 10.3390/cells8101139

M3 - Article

VL - 8

JO - Cells

JF - Cells

SN - 2073-4409

IS - 10

M1 - 1139

ER -